[1]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72-76.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(01):72-76.[doi:10.3969/j.issn.1671-7414.2018.01.001]
点击复制

多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年01期
页码:
72-76
栏目:
论著
出版日期:
2018-02-05

文章信息/Info

Title:
Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value
文章编号:
1671-7414(2018)01-072-05
作者:
盘国雄; 谭才燕; 何嘉颖; 梁梓钊
肇庆市第二人民医院,广东肇庆 526060
Author(s):
PAN Guo-xiong; TAN Cai-yan; HE Jia-ying; LIANG Zi-zhao
the Second People's Hospital of Zhaoqing City,Guangdong Zhaoqing 526060,China
关键词:
多发性骨髓瘤;  长链非编码RNA;  转录产物;  临床表达;  预后
分类号:
R733.73; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.01.001
文献标志码:
A
摘要:
目的 探究多发性骨髓瘤(MM)中血清长链非编码RNA(lncRNA)转录产物1(PCAT-1)的表达水平及临床应用价值。方法 选取肇庆市第二人民医院72例MM患者作为研究对象,另选取同期在该院进行体检的60例正常者作为对照组,RT-PCR法测定血清中lncRNA PCAT-1表达; 分析lncRNAPCAT-1的表达与临床病理参数、治疗效果的关系,采用Kaplan-Meier对5年生存情况进行分析,Log-Rank法检测生存差异。结果 MM组血清中 PCAT-1mRNA表达量2.65±0.64高于对照组1.06±0.23,差异有统计学意义(t=18.276,P=0.000)。PCAT-1 mRNA高表达组、低表达组在性别、临床分期、病理分型及血红蛋白、浆细胞、血小板、清蛋白、β2-MG和CRP方面对比,差异均无统计学意义(χ2=0.001～3.345,均P>0.05)。Ca2+≥10 mg/dl高表达组患者比例(57.14%)明显高于低表达组(27.27%),差异有统计学意义(χ2=4.157,P=0.041; χ2=5.229,P=0.022)。PCAT-1低表达组、高表达组治疗有效率对比(88.64% vs 75.00%),差异无统计学意义(χ2=2.291,P=0.130)。PCAT-1高表达、低表达组无生存进展(PFS)、总体生存(OS)曲线对比,差异有统计学意义(χ2=7.269,P=0.007; χ2=9.190,P=0.002)。COX风险回归多因素分析显示年龄、PCAT-1mRNA表达量为影响患者预后的独立因素(OR=3.275,P=0.025,95%CI:2.691～3.761; OR=2.136,P=0.046,95%CI:2.034～2.685)。结论 lncRNA PCAT-1在MM患者血清中呈高表达,并与患者的预后相关。
Abstract:
Abstract:Objective To explore serum long stranded noncoding RNA(lncRNA)transcript 1(PCAT-1)expression level of patients with multiple myeloma(MM)and clinical value.Methods 72 cases of patients with MM treated in the Second People's Hospital of Zhaoqing City were selected as the study objects,and 60 cases of normal subjects undergoing physical examination in the same period were as the control group.Serum lncRNA PCAT-1expression was detected by RT-PCR method.The relationship between lncRNA PCAT-1 expression and clinical pathological parameters,treatment effect wasanalyzed,and 5 years survival was analyzed by using Kaplan-Meier,and survivaldifference was detected by using Log-Rank method.Results Serum PCAT-1mRNA expression in MM group(2.65±0.64)was significantly higher than that in the control group(1.06±0.23,t=18.276,P=0.000).There were no significant differences in sex,clinical stage and pathological typesof hemoglobin,plasma cells,platelets,albumin,β2-MG and CRP between PCAT-1mRNA high expression group and low expression group(χ2=0.001～3.345,all P>0.05).Ca2+≥10 mg/dl in the PCAT-1 high expression group(57.14%)was significantly higher than that in the low expression group(27.27%,χ2=5.229,P=0.022).There was no significant difference in treatmenteffect between PCAT-1 mRNA high expression group and low expression group(88.64% vs 75.00%,χ2=2.291,P=0.130).PFS and OS expression in PCAT-1highexpression group were lower than that in the low expression group(χ2=7.269,P=0.007; χ2=9.190,P=0.002).COX risk regression multiple factor analysis showed that age and PCAT-1mRNA expression were independent prognostic factors influencing patients(OR=3.275,P=0.025,95%CI:2.691～3.761; OR=2.136,P=0.046,95%CI:2.034～2.685).Conclusion LncRNA PCAT-1 is highly expressed in serum of patients with multiple myeloma,and correlated with the prognosis of patients.

参考文献/References:

[1] 王 路,张翼鷟.伴髓外病变的多发性骨髓瘤研究进展[J].中国实验血液学杂志,2016,24(3):945-948. Wang L,Zhang YZ.Research progress on multiple myeloma with extramedullary disease-review[J].Journal of Experimental Hematology,2016,24(3):945-948.
[2] 李护君,李振宇,徐开林.多发性骨髓瘤的分层及微小残留病检测[J].国际输血及血液学杂志,2016,39(3):185-190. Li HJ,Li ZY,Xu KL.Stratification and minimal residual disease detection of multiple myeloma[J].International Journal of Blood Transfusion andHematology,2016,39(3):185-190.
[3] 胡 倩,姚和瑞.长链非编码RNA与肿瘤研究现状[J].中华肿瘤防治杂志,2014,21(21):1746-1750. Hu Q,Yao HR.Review on long non-coding RNA in tumor research[J].Chinese Journal of Cancer Prevention and Treatment,2014,21(21):1746-1750.
[4] 李春玲,叶 龙,陈 林,等.血清长链非编码RNACRNDE-h,GAS5检测诊断多发性骨髓瘤的价值分析[J].中国实验诊断学,2016,20(11):1844-1848. Li CL,Ye L,Chen L,et al.The value of serum long non-coding RNACRNDE-h and GAS5 in diagnosis of multiple myeloma[J].Chinese Journal of Laboratory Diagnostics,2016,20(11):1844-1848.
[5] 张之南,沈 悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:232-234. Zhang ZN,Shen T.Blood disease diagnostic and curative standard[M].3th Ed.Beijing:Science Press,2007:232-234.
[6] 罗杨婧婷,唐圣松.长链非编码RNA MEG3对肿瘤细胞调控作用的研究进展[J].临床与病理杂志,2016,36(2):185-189. Luoyang JT,Tang SS.Research advancement of long non-coding RNA MEG3 in regulating tumor cell apoptosis[J].International Journal of Pathologyand Clinical Medicine,2016,36(2):185-189.
[7] 朱昆鹏,张春林.长链非编码RNA对肿瘤耐药作用的研究进展[J].肿瘤研究与临床,2015,27(1):69-72. Zhu KP,Zhang CL.Research progress of long non-coding RNA in tumordrug resistance[J].Cancer Research and Clinic,2015,27(1):69-72.
[8] 石永国,王科明.lncRNA在消化系统肿瘤中的研究进展[J].中国肿瘤临床,2013,40(15):938-940. Shi YG,Wang KM.Long noncoding RNA in digestive system neoplasms[J].Chinese Journal of Clinical Oncology,2013,40(15):938-940.
[9] 郭倚天,许 斌,陈 明.长链非编码RNA在前列腺癌中的作用及研究进展[J].医学研究生学报,2017,30(2):199-203. Guo YT,Xu B,Chen M.Long no-coding RNAs in prostate cancer[J].Journal of Medical Postgraduatesm,2017,30(2):199-203.
[10] Shen X,Zhang Y,Wu X,et al.Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum[J].Cancer Biomarkers,2017,18(3):257-263.
[11] 党 强,周小果,仝 建.前列腺癌相关长链非编码RNA转录产物1在非小细胞肺癌组织中的表达及意义[J].中华实验外科杂志,2016,33(5):1387-1389. Dang Q,Zhou XG,Tong J.Expression of prostate cancer-associated long non-coding RNA transcripts 1 and its significance in non-small cell lung cancer[J].Chinese Journal of Experimental Surgery 2016,33(5):1387-1389.
[12] Prensner JR,Chen W,Iyer MK,et al.PCAT-1,a lo-ng noncoding RNA,regulates BRCA2 and controls homologous recombination in cancer[J].Cancer Research,2014,74(6):1651-1660.
[13] Liu L,Liu Y,Zhuang C,et al.Inducing cell growth arrest and apoptosisby silencing long non-coding RNA PCAT-1 in human bladder cancer[J].Tumor Biology,2015,36(10):7685-7689.
[14] Zhao B,Hou X,Zhan H.Long non-coding RNA PC AT-1 over-expression promotes proliferation and metastasis in non-small cell lung cancer cells[J].International Journal of Clinical & Experimental Medicine,2015,8(10):18482-18487.
[15] Yan K,Arfat Y,Li D,et al.Structure prediction:ne-w insights into decrypting long noncoding RNAs[J].International Journal of Molecular Sciences,2016,17(1):594-602.
[16] Ge X,Chen Y,Liao X,et al.Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer[J].Med Oncol,2013,30(2):588.
[17] Yan TH,Yang H,Jiang JH,et al.Prognostic significance of long non-coding RNA PCAT-1 expression in human hepatocellular carcinoma[J].Int J Clin Exp Pathol,2015,8(4):4126-4131.
[18] Shi WH,Wu QQ,Li SQ,et al.Upregulation of the long noncoding RNA PCAT-1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma[J].Tumour Biol,2015,36(4):2501-2507. 收稿日期:2017-10-20 修回日期:2017-12-20

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(01):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(01):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(01):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(01):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(01):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(01):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
　WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(01):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
[8]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[9]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(01):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[10]何　进,张　艳,申娴娟,等.多发性骨髓瘤患者血清可溶性PD-L1水平在辅助诊断及临床分型的价值研究[J].现代检验医学杂志,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
　HE Jin,ZHANG Yan,SHEN Xian-juan,et al.Value of Blood Soluble PD-L1 in the Auxiliary Diagnosis and Clinical Subtype of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(01):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]

备注/Memo

备注/Memo:
作者简介:盘国雄(1974-),男,大学本科,从事骨髓、血液细胞学及血型血清学等工作,E-mail:935805555@qq.com。 通讯作者:梁梓钊(1993-),男,大专学历,从事PCR基因检测等工作,E-mail:935805555@qq.com。
更新日期/Last Update: 2018-02-07